All In Biotech

NDA 006188 · Ph Health

Propylthiouracil

Propylthiouracil · Oral · Thyroid Hormone Synthesis Inhibitor

Last checked: Nov 20, 2026Latest source record: Sep 19, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1947

Jul 28, 1947

Approved uses

1

Original approval plus efficacy supplements

Registered trials

8

3 Phase 3, 0 recruiting

FAERS reports

2,081

1,801 serious, 181 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING Severe liver injury and acute liver failure, in some cases fatal, have been reported in patients treated with propylthiouracil. These reports of hepatic reactions include cases requiring liver transplantation in adult and pediatric patients. Propylthiouracil should be reserved for patients who cannot tolerate methimazole and in whom radioactive iodine therapy or surgery are not appropriate treatments for the management of hyperthyroidism. Propylthiouracil may be the treatment of choice when an antithyroid drug is indicated during or just prior to the first trimester of pregnancy (see Warnings and Precautions ).

What it is approved for

From the label in effect Aug 27, 2026.

INDICATIONS AND USAGE Propylthiouracil is indicated: in patients with Graves’ disease with hyperthyroidism or toxic multinodular goiter who are intolerant of methimazole and for whom surgery or radioactive iodine therapy is not an appropriate treatment option to ameliorate symptoms of hyperthyroidism in preparation for thyroidectomy or radioactive iodine therapy in patients who are intolerant of methimazole

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 28, 1947 Original approval
1 products under this application
  • PROPYLTHIOURACIL · PROPYLTHIOURACIL 50MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Propylthiouracil" as an intervention, any sponsor and status, largest first.

All 8 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective198
  • off label use153
  • hyperthyroidism140
  • foetal exposure during pregnancy119
  • nausea88
  • anti-neutrophil cytoplasmic antibody positive vasculitis87
  • exposure during pregnancy85
  • maternal exposure during pregnancy76
  • hypotension71
  • agranulocytosis61
  • pyrexia61
  • fatigue59

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200445
200539
200632
200747
200835
200930
201051
2011104
201260
201347
201479
201578
201675
201772
2018122
2019137
2020109
202197
2022102
2023188
2024231
2025205
202696

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Propylthiouracil (Propylthiouracil)

2024 spending

$2.2M

Beneficiaries

8,860

38,295 claims

Per beneficiary

$243

$0.46 per unit

View as table
YearSpending
2020$3,365,126
2021$3,201,535
2022$3,006,140
2023$2,821,053
2024$2,154,323

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 145 on PubMed

Sponsor: Ph Health

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.